Zentalis Pharmaceuticals

Third Harmonic Bio and Q32 Bio are not in imminent danger of running out of cash, but both companies recently took a look at early data for their lead drug candidates and decided to significantly cut

Nearly three and a half years after being bought by Bayer, Vividion Therapeutics has itself hit the acquisition trial to buy the US precision oncology platform company Tavros Therapeutics. Vividion sa

Cancer treatment has transformed over the last 25 years. Since the first genetically targeted treatments emerged in the 1990s and immune checkpoint inhibitors in the 2010s, oncology has consistently o

The market for initial public offerings in the US looks like it might be waking up from a month and a half nap with one biopharmaceutical company making it through the IPO window in mid-June and three